

Masanori Atsukawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2856594/publications.pdf>

Version: 2024-02-01

86
papers

1,974
citations

257101

24
h-index

301761

39
g-index

95
all docs

95
docs citations

95
times ranked

1899
citing authors

#	ARTICLE	IF	CITATIONS
1	Does first-line treatment have prognostic impact for unresectable HCC? Atezolizumab plus bevacizumab versus lenvatinib. <i>Cancer Medicine</i> , 2023, 12, 325-334.	1.3	25
2	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. <i>Cancer Reports</i> , 2022, 5, e1464.	0.6	43
3	Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. <i>Hepatology Research</i> , 2022, 52, 235-246.	1.8	7
4	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. <i>Hepatology Research</i> , 2022, 52, 462-470.	1.8	18
5	Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0263844.	1.1	5
6	Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C. <i>Hepatology Communications</i> , 2022, 6, 1855-1869.	2.0	3
7	Type III procollagen peptide level can indicate liver dysfunction associated with volume overload in acute heart failure. <i>ESC Heart Failure</i> , 2022, 9, 1832-1843.	1.4	5
8	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC stage patients classified as beyond up to seven criteria – Multicenter analysis. <i>Hepatology Research</i> , 2022, 52, 308-316.	1.8	25
9	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. <i>Cancer Medicine</i> , 2022, 11, 3796-3808.	1.3	21
10	The best predictive model for post-SVR HCC: can it be universal?. <i>Hepatology International</i> , 2022, 16, 728-728.	1.9	3
11	Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment. <i>Current Oncology</i> , 2022, 29, 3259-3271.	0.9	2
12	Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease. <i>Scientific Reports</i> , 2022, 12, 7311.	1.6	1
13	Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1231-1234.	0.8	2
14	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Scientific Reports</i> , 2022, 12, 8421.	1.6	4
15	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. <i>Hepatology Research</i> , 2022, 52, 773-783.	1.8	34
16	International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2022, 29, 807-816.	1.0	4
17	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1812-1819.	1.4	28
18	Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease. <i>Digestive Diseases</i> , 2021, 39, 234-242.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. <i>Hepatology Research</i> , 2021, 51, 201-215.	1.8	22
20	Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 269-280.	1.8	0
21	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. <i>Gastroenterology Report</i> , 2021, 9, 133-138.	0.6	21
22	Development of interferon-free, direct-acting antivirals treatment for Japanese patients with chronic hepatitis C infection and chronic kidney disease. <i>Journal of Nippon Medical School</i> , 2021, 88, 163-170.	0.3	4
23	Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis. <i>Oncology</i> , 2021, 99, 518-527.	0.9	5
24	Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110002.	1.4	21
25	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. <i>Liver Cancer</i> , 2021, 10, 115-125.	4.2	12
26	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. <i>Liver International</i> , 2021, 41, 1389-1397.	1.9	45
27	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. <i>Hepatology International</i> , 2021, 15, 366-379.	1.9	71
28	Increased Frequency of Dysfunctional Siglec-7 ⁺ CD57 ⁺ PD-1 ⁺ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2021, 12, 603133.	2.2	13
29	Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. <i>American Journal of Gastroenterology</i> , 2021, 116, 1264-1273.	0.2	12
30	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i> , 2021, 51, 880-889.	1.8	15
31	Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. <i>Hepatology</i> , 2021, 74, 656-666.	3.6	31
32	Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial. <i>Nutrients</i> , 2021, 13, 1874.	1.7	10
33	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2021, 41, 2997-3008.	1.9	18
34	Clinical Significance of the Fibrosis-4 Index in Patients with Acute Heart Failure Requiring Intensive Care. <i>International Heart Journal</i> , 2021, 62, 858-865.	0.5	7
35	Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. <i>Scientific Reports</i> , 2021, 11, 14474.	1.6	13
36	Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 15938.	1.6	21

#	ARTICLE	IF	CITATIONS
37	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. <i>Scientific Reports</i> , 2021, 11, 16663.	1.6	30
38	A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. <i>PLoS ONE</i> , 2021, 16, e0257166.	1.1	5
39	Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 261-268.	0.8	9
40	Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, , .	1.4	1
41	Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. <i>Investigational New Drugs</i> , 2020, 38, 172-180.	1.2	57
42	Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 855-861.	1.4	23
43	Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. <i>Liver Cancer</i> , 2020, 9, 73-83.	4.2	37
44	Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching. <i>Hepatology Research</i> , 2020, 50, 75-83.	1.8	44
45	Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1229-1237.	1.4	13
46	<p>Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis<p>. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 385-396.	1.0	34
47	Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 382-396.	4.2	54
48	Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization. <i>Hepatology Research</i> , 2020, 50, 1244-1254.	1.8	18
49	Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 851-866.	1.8	16
50	The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. <i>Hepatology International</i> , 2020, 14, 225-238.	1.9	25
51	Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2020, 98, 295-302.	0.9	24
52	Neutrophil-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2020, 40, 968-976.	1.9	51
53	Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 293.	1.7	34
54	Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1420-1425.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Usefulness of autotaxin for the complications of liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2020, 26, 97-108.	1.4	7
56	Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 364-369.	1.4	26
57	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019, 97, 277-285.	0.9	66
58	Evaluation of 8â€week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1266-1275.	1.0	13
59	Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C. <i>PLoS ONE</i> , 2019, 14, e0219022.	1.1	2
60	Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2019, 14, e0224184.	1.1	13
61	Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2019, 97, 334-340.	0.9	39
62	Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, 1036-1042.	0.4	36
63	Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz185.	0.4	18
64	Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditionsâ€Multicenter analysis. <i>Cancer Medicine</i> , 2019, 8, 3719-3728.	1.3	131
65	Circulating microRNAâ€1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma. <i>Hepatology Research</i> , 2019, 49, 810-822.	1.8	27
66	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. <i>Cancer Medicine</i> , 2019, 8, 137-146.	1.3	112
67	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. <i>Hepatology Research</i> , 2019, 49, 369-376.	1.8	9
68	Advances in Antiviral Therapy in Patients with Chronic Hepatitis C. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2019, 15, 106-114.	0.0	0
69	Title is missing!. , 2019, 14, e0224184.		0
70	Title is missing!. , 2019, 14, e0224184.		0
71	Title is missing!. , 2019, 14, e0224184.		0
72	Title is missing!. , 2019, 14, e0224184.		0

#	ARTICLE	IF	CITATIONS
73	Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1256-1263.	1.4	20
74	Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. <i>Journal of Gastroenterology</i> , 2018, 53, 566-575.	2.3	107
75	Efficacy and Safety of Glecaprevir/Pibrentasvir Combination Therapy in Genotype 1b Chronic Hepatitis C Patients with and without Cirrhosis Undergoing Hemodialysis. <i>Acta Hepatologica Japonica</i> , 2018, 59, 578-580.	0.0	1
76	Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. <i>PLoS ONE</i> , 2018, 13, e0200664.	1.1	13
77	Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. <i>Journal of Gastroenterology</i> , 2018, 53, 1276-1284.	2.3	25
78	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. <i>Hepatology</i> , 2018, 67, 505-513.	3.6	94
79	Relationship between response to lusutrombopag and splenic volume. <i>World Journal of Gastroenterology</i> , 2018, 24, 5271-5279.	1.4	22
80	Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2017, 49, 1029-1035.	0.4	21
81	Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. <i>Hepatology Research</i> , 2017, 47, 1429-1437.	1.8	41
82	Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. <i>Hepatology Research</i> , 2017, 47, 1308-1316.	1.8	36
83	Efficacy and safety of elbasvir and grazoprevir for chronic hepatitis C patients with chronic kidney disease. <i>Acta Hepatologica Japonica</i> , 2017, 58, 678-680.	0.0	1
84	Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. <i>World Journal of Hepatology</i> , 2015, 7, 2590.	0.8	5
85	Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 781-787.	0.8	3
86	Ribavirin downmodulates inducible costimulator on CD4 ⁺ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 823-831.	1.4	20